The study also showed a significant effect on the appearance of acne lesions as early as three weeks.
Sygenus is a patented allogeneic cell secretions technology platform that comprises cytokines, growth factors and exosomes from adipose-derived mesenchymal stem cells.
Bioactive molecules reduce pain and inflammation
Bioactive molecules work to reduce pain and inflammation and encourage accelerated healing and repair.
The tolerance study, performed by RCTS, a dermatology testing company in Texas, examined the tolerability of Sygenus in 33 healthy volunteers with mild to moderate facial acne.
The study endpoints to assess tolerability involved the change in acne lesions over the 6-week period when Sygenus gel was applied topically twice a day.
Overall improvement achieved as early as three weeks
No intolerance was observed and there was an overall improvement in the appearance of acne, as early as 3 weeks.
Statistically significant reductions in the total number of inflammatory and non-inflammatory acne lesions were noted from baseline to week 6.
The acne global severity score also showed significant reduction (improvement) at week 6 compared to baseline.
Strong demand for new acne treatments
These promising results will help in the partnering of Sygenus gel for the acne market and other inflammatory skin conditions.
With few treatment innovations or improvements without significant side effects in the treatment of acne over the last 10 years, the demand for improved acne treatments is high.
Regeneus has patents in Australia, Europe, China, Japan and the US covering the composition, manufacture and use of Sygenus technology for the topical treatment of acne.
The company also has patent applications for the use of Sygenus for a broad range of other inflammatory skin conditions.
Potential pain relief applications
A key area of research focus is the use of Sygenus technology for the treatment of pain.
A preclinical post-operative pain study has shown that topical application of Sygenus has significant and longer lasting analgesic effects than an injection of morphine.
Regeneus is also investigating the use of its stem cell technologies for the treatment of pain in an ARC Linkage program with the University of Adelaide and Macquarie University.